BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 17467579)

  • 1. Translational research in the pharmaceutical industry: from theory to reality.
    Sultana SR; Roblin D; O'Connell D
    Drug Discov Today; 2007 May; 12(9-10):419-25. PubMed ID: 17467579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational research in the pharmaceutical industry: from bench to bedside.
    O'Connell D; Roblin D
    Drug Discov Today; 2006 Sep; 11(17-18):833-8. PubMed ID: 16935752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers: a valuable tool in clinical research and medical practice.
    Carini C
    IDrugs; 2007 Jun; 10(6):395-8. PubMed ID: 17642003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Promises of biomarkers in drug development--a reality check.
    Marrer E; Dieterle F
    Chem Biol Drug Des; 2007 Jun; 69(6):381-94. PubMed ID: 17581232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ultimate model organism: progress in experimental medicine.
    Littman BH; Williams SA
    Nat Rev Drug Discov; 2005 Aug; 4(8):631-8. PubMed ID: 16056389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What's next in translational medicine?
    Littman BH; Di Mario L; Plebani M; Marincola FM
    Clin Sci (Lond); 2007 Feb; 112(4):217-27. PubMed ID: 17223795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying computational modeling to drug discovery and development.
    Kumar N; Hendriks BS; Janes KA; de Graaf D; Lauffenburger DA
    Drug Discov Today; 2006 Sep; 11(17-18):806-11. PubMed ID: 16935748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Big pharma slims down to bolster productivity.
    Owens J
    Nat Rev Drug Discov; 2007 Mar; 6(3):173-4. PubMed ID: 17396286
    [No Abstract]   [Full Text] [Related]  

  • 11. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytomics and drug discovery.
    Van Osta P; Ver Donck K; Bols L; Geysen J
    Cytometry A; 2006 Mar; 69(3):117-8. PubMed ID: 16496374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomic approaches in clinical studies to identify biomarkers of safety and efficacy.
    Burczynski ME
    Toxicol Lett; 2009 Apr; 186(1):18-21. PubMed ID: 19022363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic success via targeted approaches and strategic partnerships with clinical laboratories.
    Miller GA
    IDrugs; 2007 Mar; 10(3):181-4. PubMed ID: 17351872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional human tissue assays.
    Hillier C; Bunton D
    Drug Discov Today; 2007 May; 12(9-10):382-8. PubMed ID: 17467574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
    Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
    Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
    [No Abstract]   [Full Text] [Related]  

  • 17. [Drug development--from receptor research to therapy].
    Lammintausta R; Scheinin M
    Duodecim; 1998; 114(10):957-66. PubMed ID: 11524784
    [No Abstract]   [Full Text] [Related]  

  • 18. Implications of pharmacogenomics for drug development.
    Kirk RJ; Hung JL; Horner SR; Perez JT
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedside-to-bench pharmacology: a complementary concept to translational pharmacology.
    Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 2010 Jun; 87(6):647-9. PubMed ID: 20485323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
    Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
    Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.